Grimes & Company’s Insmed INSM Stock Holding History

Grimes & Company’s Portfolio INSM Stock Details INSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,000	Closed	-$348K	–	456
2025 Q4	$348K	Hold	2,000	–	–	0.01%	358
2025 Q3	$288K	Buy	+2,000	New	+$245K	0.01%	382

Other funds holding INSM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Grimes & Company's INSM Position: Q1 2026 in Review

Grimes & Company sold out of Insmed (INSM) in Q1 2026, closing a stake of 2,000 shares — an estimated $348K sold.

Grimes & Company first reported a position in INSM in Q3 2025 and held it in 2 quarters. The position peaked at $348K in Q4 2025. 673 funds tracked by Wall St. Rank hold INSM as of Q1 2026.

Grimes & Company reported no remaining Insmed position as of Q1 2026 after selling out during the quarter.
Grimes & Company sold 2,000 Insmed shares in Q1 2026, an estimated $348K.
Grimes & Company first reported a position in Insmed in Q3 2025 and held it in 2 quarters.
Grimes & Company's Insmed position peaked at $348K in Q4 2025.
673 funds tracked by Wall St. Rank held Insmed as of Q1 2026.

Based on Grimes & Company's 13F filing for Q1 2026, filed 21 Apr 2026.